Comparing the current results to its competitors, Gilead Sciences Inc reported Revenue increase in the 2 quarter 2026 by 10.18 % year on year. The revenue growth was below Gilead Sciences Inc 's competitors' average revenue growth of 13.02 %, achieved in the same quarter.
Gilead Sciences Inc , slower than the average decrease reported by the company's competitors of -55.82 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -55.82 %
Gilead Sciences Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment where its products are evaluated based on efficacy, safety, tolerability, physician acceptance, patient compliance, ease of use, price, insurance coverage, distribution, and marketing. It faces competition from large pharmaceutical and biotechnology companies, specialized pharmaceutical firms, academic institutions, government agencies, and other public and private research organizations. Additional competitive pressures include pricing challenges from private insurers and government payers, as well as the introduction of new branded or generic products in major markets.
Overall company revenue, increased less, than total company revenues, at 10.18 % and lost market share, to approximately 5.35 %. << More on GILD Market Share.
*Market share is calculated based on total revenue.
November 7, 2025
Gilead s ASCENT-07 Study Update: A Mixed Bag Amidst Competitive Pressure in the Pharmaceutical Sector Foster City, California - Gilead Sciences, Inc. (Nasdaq: GILD) has recently provided an update regarding its Phase 3 ASCENT-07 study, which aimed to evaluate the efficacy of Trodelvy (sacituzumab govitecan-hziy) as a first-line treatment in patients with HR+/HER2-negative metastatic breast cancer after endocrine therapy. The company announced that the study did not meet its primary endpoint of progression-free survival (PFS) when assessed by Blinded Independent Central Review (BICR) according to the RECIST v1.1 criteria. This news marks a significant setback in Gilead’s efforts to enhance its oncology port...
February 24, 2025
In a significant advancement for public health, Gilead Sciences, Inc. (Nasdaq: GILD) has made noteworthy strides in its drug development efforts, as evidenced by recent announcements regarding two of its investigational therapies: lenacapavir and seladelpar. These developments could have profound implications for both HIV prevention and the treatment of primary biliary cholangitis (PBC), highlighting Gilead s ongoing commitment to addressing unmet medical needs. Lenacapavir: A Breakthrough in HIV PreventionThe European Medicines Agency (EMA) recently validated Gilead s Marketing Authorization Application (MAA) and EU-Medicines for All (EU-M4all) request for lenacapavir, a twice-yearly injectable HIV-1 capsid...
November 28, 2024
Gilead Sciences: A Competitive Edge in HIV Prevention Amidst Mixed Financial PerformanceIn a significant stride for HIV prevention, Gilead Sciences, Inc. (NASDAQ: GILD) recently announced the publication of the full results from its pivotal Phase 3 PURPOSE 2 trial in the New England Journal of Medicine (NEJM). This landmark study demonstrates the high efficacy of lenacapavir, an investigational agent used for pre-exposure prophylaxis (PrEP), when administered twice yearly to a diverse group of cisgender men and gender-diverse individuals. This announcement not only reflects Gilead s commitment to innovation in the field of HIV prevention but also highlights the company s strategic positioning amidst a compe...
November 5, 2024
Kite, a Gilead Company, is poised to make a significant impact at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH 2024), scheduled for December 7-10 in San Diego, California. The biopharmaceutical leader in CAR T-cell therapy is set to present robust data showcasing the effectiveness of its innovative therapies across a variety of blood cancers. With a total of 18 presentations, including six distinguished oral presentations, Kite aims to reinforce its position as a frontrunner in cancer treatment.Kite s presentations will emphasize its ongoing commitment to advancing CAR T-cell therapies, which have been transformative for patients facing hematological malignancies. The dat...
October 2, 2024
In an ambitious stride towards boosting global health equity, Gilead Sciences, Inc. has recently announced the signing of non-exclusive, royalty-free voluntary licensing agreements with six generic pharmaceutical manufacturers. This strategic decision aims to facilitate the production and distribution of lenacapavir, a novel therapeutic agent for HIV prevention, across 120 high-incidence, resource-limited countries. Predominantly targeting low- and lower-middle-income nations, these agreements signify Gilead s commitment to expanding healthcare access and combating the HIV epidemic on a global scale.The agreements were forged in anticipation of future regulatory approvals, allowing these manufacturers to ini...
September 5, 2024
Gilead Sciences: Advancements in Lung Cancer, Primary Biliary Cholangitis, and HIV Treatments Gilead Sciences, Inc. (Nasdaq: GILD) has recently demonstrated significant strides across various facets of pharmaceutical research and development. The company is set to unveil new data regarding its lung cancer clinical development program at the IASLC 2024 World Conference on Lung Cancer. Furthermore, Gilead has achieved a milestone with the accelerated approval of Livdelzi (seladelpar) for primary biliary cholangitis by the U.S. FDA and disclosed impactful research findings from its innovative HIV treatment portfolio. Trodelvy (sacituzumab govitecan-hziy) in Lung Cancer Gilead Sciences will present pioneering da...
August 15, 2024
In a significant development for patients suffering from primary biliary cholangitis (PBC), Gilead Sciences, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Livdelzi (seladelpar). This approval offers new hope for adults who have had inadequate responses to the conventional treatment regime using ursodeoxycholic acid (UDCA) or those who cannot tolerate this therapy.PBC is an autoimmune disease that progressively damages the bile ducts in the liver, leading to serious complications if left untreated. Patients commonly receive UDCA as a first-line treatment; however, not all patients respond adequately, necessitating alternative therapies to mitigate liv...
August 14, 2024
Gilead Sciences Advances Healthcare Solutions: Accelerated Approval of Livdelzi and Innovations in HIV Prevention FOSTER CITY, Calif. Gilead Sciences, Inc. (Nasdaq: GILD) has made significant strides in the landscape of healthcare, as evidenced by two crucial announcements that promise to enhance treatment options for patients suffering from serious health conditions. The U.S. Food and Drug Administration (FDA) granted accelerated approval for Gilead’s Livdelzi (seladelpar) for the treatment of primary biliary cholangitis (PBC), while also showcasing groundbreaking advancements in HIV prevention with the investigational double annual injection of lenacapavir. Accelerated Approval of Livdelzi (Seladelp...
July 22, 2024
Gilead Sciences, Inc. (Nasdaq: GILD) and the Elton John AIDS Foundation (EJAF) have announced the extension of their RADIAN partnership for an additional five years, with an unwavering focus on tackling the intensifying HIV crisis in Eastern Europe and Central Asia (EECA). Despite confronting broader financial pressures and rising competition within the pharmaceutical industry, Gilead remains resolutely dedicated to its mission of addressing HIV-related challenges. Renewed Commitment to Combat HIVThe RADIAN initiative, originally conceived as a response to the disproportionately high rates of HIV in EECA, aims to support the most vulnerable populations in this region. As global HIV rates decline, the situati...
June 20, 2024
Breaking New Ground in HIV Prevention: Gilead s Lenacapavir Delivers 100% EfficacyGilead Sciences, Inc. (Nasdaq: GILD) has recently unveiled groundbreaking data from its Phase 3 PURPOSE 1 trial, showcasing the impressive efficacy of its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir. In a major breakthrough for HIV prevention, the trial demonstrated that lenacapavir achieved 100% efficacy in cisgender women, surpassing the once-daily oral Truvada.The interim analysis of the trial s results exhibited lenacapavir s superiority over Truvada in meeting key efficacy endpoints. Truvada, containing emtricitabine 200mg and tenofovir disoproxil fumarate 300mg, has long been the go-to medication for pre-e...
AbbVie Inc operates primarily as a global biopharmaceutical company, focusing on the research, development, manufacturing, and commercialization of advanced therapies and medications in critical areas such as immunology, oncology, neuroscience, and virology. The company aims to improve patient outcomes and address unmet medical needs by leveraging its scientific expertise and capabilities while providing value to stakeholders in the healthcare industry.
Johnson & Johnson operates as a multinational healthcare company with a diversified business model that spans pharmaceuticals, medical devices, and consumer health products. By focusing on innovation and strategic acquisitions, the company aims to improve global health and well-being.
Merck & Co. Inc. operates primarily as a research-driven pharmaceutical company, focused on the development, manufacturing, and marketing of prescription drugs and vaccines globally. It aims to address unmet medical needs through innovative research, collaborations, and rigorous clinical trials, while promoting patient well-being and contributing to global healthcare with high-quality, affordable medications.
Bristol Myers Squibb Company operates a research and development-driven business model, focusing on the discovery and delivery of innovative medicines for various diseases. It emphasizes collaboration with academic institutions, government entities, and other pharmaceutical firms to enhance its therapeutic portfolio and improve patient outcomes.
Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.
Sources:
Gilead Sciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Gilead Sciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
